G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required  by Zaucha, J.Maciej et al.
613B B & M T
INTRODUCTION
Recent studies have indicated that high-risk patients
receiving granulocyte colony-stimulating factor (G-CSF)–
mobilized peripheral blood mononuclear cells (G-PBMCs)
in place of marrow as a source of allogeneic hematopoietic
stem cells after myeloablative conditioning regimens experi-
ence a survival advantage [1,2] as well as faster platelet and
neutrophil recoveries [2-4]. Although the faster engraftment
kinetics have been associated with increased numbers of
CD34 cells, the biological basis for the survival advantage is
less clear. Considerable effort is now focused on both quali-
tative and quantitative comparisons of these 2 stem cell
sources to understand their differences and thereby opti-
mize stem cell products.
These efforts have shown that immunobiologic proper-
ties of G-PBMC products differ from marrow grafts [5].
Studies in mice demonstrated that G-PBMC reduces severity
of acute graft-versus-host disease (GVHD) [6]. T lympho-
cytes of dogs treated with recombinant canine G-CSF were
found to be hyporesponsive when assayed in the mixed lym-
phocyte cultures and with concanavalin A [7]. Early reports
from human studies showed that despite the approximately
1- to 2-log increase in the number of T lymphocytes present
in G-PBMC products, the risk of acute GVHD was no
greater with G-PBMC than with conventional HLA-identical
sibling marrow grafts [8-10]. Postgrafting immunosuppres-
sion could in part explain this ﬁnding; however, in vitro stud-
ies showed that G-CSF stimulation changed the function of
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ABSTRACT
Stable mixed donor/host hematopoietic chimerism can be uniformly established in dogs conditioned with 200 cGy
TBI before dog leukocyte antigen (DLA)-identical marrow transplantation and immunosuppressed with a short
course of mycophenolate mofetil (MMF) and cyclosporine (CSP) after the transplantation. A further decrease in the
TBI dose to 100 cGy or the elimination of MMF in this model results in graft rejection. Here we asked whether the
addition of G-CSF–mobilized peripheral blood mononuclear cells (G-PBMC) to marrow grafts would enhance
donor engraftment in dogs conditioned with 100 cGy TBI and given postgrafting immunosuppression with CSP
alone. Using this model, 7 of 9 dogs given only marrow cells rejected their grafts within 8 to 17 weeks after trans-
plantation. In contrast, the addition of unmodified G-PBMC to marrow grafts resulted in stable mixed donor/host
chimerism in 5 of 8 dogs studied (P = .06). However, addition of the CD3-depleted fraction of G-PBMC, which con-
tained both CD34 cells and CD14 cells, resulted in engraftment in only 1 of 7 recipients. We conclude that adding
G-PBMC to marrow grafts replaced the requirement of MMF and 100 cGy of TBI, and that CD3 cells were
required to facilitate engraftment of marrow cells in DLA-identical recipients, whereas the additional CD34 cells
present in G-PBMC were not sufficient for this effect.
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T cells. Speciﬁcally, lymphocytes from G-PBMC products
are polarized toward T helper 2 cells [11,12] and are hypore-
sponsive to alloantigen and mitogen stimulation [13,14].
Additional studies indicated that the impairment of
T-cell proliferative responses was associated with decreased
induction of the CD28 response complex following T-cell
receptor stimulation [15]. This in turn was mediated by the
large population of CD14 cells present in G-PBMC grafts
[16]. The CD14 cells were found to secrete increased
amounts of interleukin-10 (IL-10), which inhibits T-cell
proliferation and γ interferon production. The CD14 cells
also have reduced expression of HLA-DR, as well as B7.2
(CD86), a costimulatory molecule needed for T-cell activa-
tion [17]. Based on these findings, we hypothesized that
G-PBMC might provide immunosuppressive effects in vivo
that could inhibit both graft-versus-host and host-versus-
graft reactions, thereby facilitating alloengraftment after
nonmyeloablative hematopoietic stem cell transplantation.
To test this hypothesis, we used an established canine
transplantation model of dog leukocyte antigen (DLA)-
identical littermate marrow grafts in which the end point of
transplantation, stable mixed donor/host hematopoietic
chimerism, can be established after nonmyeloablative con-
ditioning. Specifically, mixed chimerism can generally be
achieved using a sublethal exposure of 200 cGy total body
irradiation (TBI) before and a combination of the immuno-
suppressive agents mycophenolate mofetil (MMF) and
cyclosporine (CSP) after marrow transplantation. Decreas-
ing the TBI dose to 100 cGy or eliminating the MMF in
this model resulted in graft rejection within 12 weeks [18].
Here, we used the canine model to ask whether the addi-
tion of G-PBMC to marrow facilitated the establishment of
stable mixed chimerism after 100 cGy TBI and using only
CSP postgrafting.
MATERIALS AND METHODS
Experimental Animals
Litters of random-bred dogs were raised at the Fred
Hutchinson Cancer Research Center (FHCRC) or pur-
chased from commercial kennels licensed by the US Depart-
ment of Agriculture. The dogs weighed from 6.5 to 16 kg
(median, 14.9 kg) and were 6 to 15 months (median,
9 months) old. Dogs were observed for disease for at least
60 days before entering the study. All were immunized for
leptospirosis, papillomavirus, distemper, hepatitis, and par-
vovirus. Research was conducted according to the principles
outlined in the Guide for Laboratory Animal Facilities and Care
(National Academy of Sciences, National Research Coun-
cil), and the Institutional Animal Care and Use Committee
of the FHCRC approved the research protocol. Kennels
were certiﬁed with the American Association for Accredita-
tion of Laboratory Animal Care. Littermate donor/recipient
pairs were chosen on the basis of DLA identity for highly
polymorphic major histocompatibility complex (MHC) class
I and class II microsatellite markers [19], as well as sequenc-
ing for canine DLA DRB1 genes [20].
Study Design
The day of hematopoietic stem cell grafting was desig-
nated as day 0. Marrow for transplantation was collected
from the donors on day –30 and cryopreserved as previ-
ously described [21]. On days –5 to 0, donors were treated
by subcutaneous injection with recombinant canine G-CSF
(gift from Amgen, Thousand Oaks, CA) at 10 µcg/kg per
day. Leukaphereses were performed on day 0 using arterio-
venous shunts and a continuous flow blood separator
(CobeSPECTRA, Cobe Laboratories, Lakewood, CO) [7].
On day 0, recipients were given a single dose of 100 cGy
TBI delivered at 7 cGy/min either from 2 opposing cobalt-
60 sources [22] or a high-energy linear accelerator (Varian
CLINAC 4, Palo Alto, CA). Both sources were calibrated
to deliver 7 cGy or 9.3 R per minute and were shown to
have the same biological effect on granulocyte and lympho-
cyte counts in dogs that did not receive transplantations.
Three groups of recipients were studied. Control recipients
in group 1 received marrow cells only. Recipients in group 2
received unmodiﬁed G-PBMC in addition to marrow cells.
Recipients in group 3 received CD3-depleted G-PBMC in
addition to marrow cells. Postgrafting immunosuppression
consisted of CSP only, 15 mg/kg twice daily orally, on days –1
to 35. Blood CSP levels were measured on days 7 and 21 to
ensure that adequate immunosuppression was achieved in
all recipients. CSP levels were measured using the Cyclo-
sporine Monoclonal Whole Blood Assay (Abbott Laborato-
ries, Abbott Park, IL) involving a ﬂuorescence polarization
[23]. Dogs with poor compliance to the liquid formulation
of CSP (a gift from SangStat Medical, Menlo Park, CA)
were given CSP in gel capsules (Neoral, Novartis Pharma-
ceutical, East Hanover, NJ). All dogs were given standard
postgrafting care that included twice-daily oral nonab-
sorbable antibiotics, neomycin sulfate and polymyxin sul-
fate combined with systemic enrofloxacin (Baytril), from
day –5 until hematopoietic recovery from radiation nadirs
occurred. The clinical status of the dogs was assessed
twice daily. The end point of the study was the incidence
and duration of mixed hematopoietic chimerism. Upon
completion of the study, dogs were euthanized, adopted, or
transferred to other studies. When euthanized, they under-
went complete necropsies with histological examinations of
tissue samples.
Cell Selection
Cell selection was performed using the CliniMACS
system (Miltenyi Biotec, Auburn, CA). G-PBMCs were
resuspended in Hank’s Balanced Salt Solution supple-
mented with 2% heat inactivated horse serum (HBSS/2%
HS) and centrifuged at 200g for 6 minutes to remove
platelets. For CD3 selection, cells were stained with a
canine-specific biotin conjugated anti-CD3ε monoclonal
antibody 17.6F9 [24] (kindly provided by Dr. Peter F.
Moore, UC Davis, Davis, CA) for 20 minutes at 4°C. After
incubation, cells were washed with HBSS/2%HS followed
by Miltenyi buffer (phosphate-buffered saline without Ca2+
or Mg2+ and 1mmol/L EDTA) supplemented with 0.5%
biotin-free bovine serum albumin (Sigma, St. Louis, MO)
and stained with 100 µL/108 cells streptavidin microbeads
(Miltenyi Biotec) for 20 minutes. Cells were filtered
through a 40 µm PALL filter (PALL Biomedical, Fajardo,
PR) prior to being loaded onto the selection column.
Depletion program 1.1 was used. Median CD3 depletion
efficiency was 1.5 (1.1–2.0) log.
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Cell Enumeration
Marrow and G-PBMC products were assessed for
CD3, CD34, and CD14 cell content by flow cytometry
FACScan (Becton Dickinson, San Jose, CA) on the day of
collection. CD3 cells were stained with the fluorescein-
conjugated 17.6B3 antibody (provided by Dr. Peter Moore,
UC Davis, Davis, CA) that recognizes a distinct CD3 epi-
tope from 17.6F9. CD34 cells were stained with the canine-
specific 1H6 antibody [25] (generous gift of Dr. Richard
Nash, FHCRC, Seattle, WA). CD14 cells were stained with
unconjugated TUK4 (anti-CD14, DAKO, Carpinteria,
CA), which cross-reacts with canine monocytes [26]. The
absolute numbers of CD3, CD34, and CD14 cells infused
were calculated by multiplying the percentage of each cell
subset by the total number of nucleated cells quantiﬁed by
an automated leukocyte counter (Sysmex E 2500, Kobe,
Japan). The numbers of infused marrow CD3, CD14, and
CD34 cells were corrected by the percentage of cells recov-
ered after thawing.
The total numbers of cells infused from G-PBMC
were adjusted in group 2 to maintain a CD3 cell dose of
approximately 2 × 108/kg. In the CD3-depleted group, the
primary objective was to infuse high numbers of CD34
cells. Therefore, the total cell doses infused in the CD3-
depleted group were deliberately higher compared to the
calculated doses of non-CD3 cells given to recipients of
unfractionated G-PBMC.
Assessment of Engraftment and Chimerism
Marrow engraftment was assessed by sustained recover-
ies of granulocyte and platelet counts after the postirradia-
tion nadirs, by histologic features of the marrow from
biopsy specimens, and by documentation of donor cells in
the marrow, lymph nodes, and granulocyte and mononuclear
cell populations from the peripheral blood using polymor-
phic microsatellite markers in a polymerase chain reaction–
based assay [27]. The assay has the sensitivity to detect
donor or host cells to a level of 1% of the total cell popula-
tion. Graft rejection was defined as the disappearance of
donor cells and exclusive presence of host cells. Blood for
chimerism analyses was obtained weekly, and the cells were
fractionated by Ficoll-Hypaque gradient centrifugation.
Statistical Analyses
Data were presented as means ± 1 standard deviation. A
2-sample t test was used for comparing mean CD34, CD3,
and CD14 cell doses among study groups. The log-rank test
was used to determine statistical signiﬁcance of differences
between incidence and duration of mixed chimerism.
RESULTS
Cell Composition of the Grafts
Table 1 shows the mean total doses of CD34, CD3, and
CD14 cells infused in the 3 groups of dogs studied. Figure 1
shows the doses of CD34, CD3, and CD14 cells given to
each recipient. Dogs in group 2 (+ G-PBMC) received
signiﬁcantly more CD3 (P < .0001) and CD14 (P < .0001)
cells than did dogs in the control group. Dogs in group 3
(CD3-depleted) received signiﬁcantly more CD34 (P = .01)
and CD14 (P < .0001) cells than did the control group,
whereas the number of CD3 cells was similar (P = .34). The
differences in CD3 and CD14 cell doses between the control
group and study groups resulted from the addition of cells
from unmodiﬁed or fractionated G-PBMC. In contrast, the
CD34 cell doses were affected both by the variations in mar-
row CD34 cell numbers and the numbers of CD34 cells
added from unmodiﬁed or fractionated G-PBMC.
Engraftment
Unmodified Viable G-PBMC Facilitated Engraftment of
Marrow Cells. All 9 control dogs in group 1, given marrow
only, had initial engraftment as evidenced by mixed
donor/host chimerism, with donor contributions ranging
from 8% to 25% at week 5 posttransplantation (Figure 2).
Subsequently, 7 dogs rejected their grafts between 8 and
17 weeks and survived with complete autologous recovery,
whereas 2 dogs achieved stable mixed donor/host chimerism
lasting for more than 30 weeks (Table 2). All 8 recipients
given unmodified G-PBMC in addition to marrow also
showed initial engraftment with 30% to 80% donor granu-
locytes at week 5. Subsequently, 5 dogs developed stable
mixed chimerism for more than 30 weeks, whereas 3 dogs
rejected their grafts between 9 and 18 weeks. Log-rank
comparison of the duration of mixed chimerism in the con-
trol group to that in the G-PBMC group strongly suggested
that the addition of unmodified G-PBMC enhanced the
development of mixed chimerism (P = .06).
CD3-Depleted G-PBMC Fraction Failed To Enhance
Engraftment of Marrow Cells. 
Seven dogs received, in addition to marrow cells, CD3-
depleted G-PBMCs, which contained large numbers of
CD34 and CD14 cells. All 7 dogs engrafted. Subsequently,
1 dog developed stable mixed chimerism, whereas 6 rejected
Table 1. Total Mean CD34, CD3, and CD14 Cell Doses Infused in Each Group
Mean Cell Dose
Group CD34, × 106/kg ± SD P* CD3, × 108/kg ± SD P* CD14, × 108/kg ± SD P*
Group 1: control† 5.96 ± 3.65 — 0.31 ± 0.14 — 0.26 ± 0.1 —
Group 2: +G-PBMC 7.57 ± 4.68 .44 1.86 ± 0.53 <.0001 2.20 ± 0.63 <.0001
Group 3: +CD3 depleted 12.9 ± 6.03 .01 0.25 ± 0.09 .34 1.58 ± 0.32 <.0001
*Two-sample t test, results in groups 2 and 3 were compared to those of controls (Group 1).
†The control group received cryopreserved marrow only. Group 2 received unfractionated G-PBMC in addition to cryopreserved marrow.
Group 3 received CD3-depleted G-PBMC in addition to cryopreserved marrow. All recipients received 100 cGy TBI for conditioning and were
treated with cyclosporine A at a dose of 15 mg/kg orally b.i.d. from day –1 to day 35.
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their grafts between 8 and 18 weeks after transplantation
and survived with complete autologous recovery (Table 2).
Comparison of the duration of mixed chimerism between
the CD3-depleted and control group showed no signiﬁcant
difference (P = .70).
Donor Chimerism
In all dogs studied, the contributions of donor cells to
peripheral blood cell populations were greater in the granu-
locyte than in the mononuclear cell fractions (Figure 2).
Donor cells were seen as early as 2 weeks after transplanta-
tion, continued to increase until weeks 5 to 6 after trans-
plantation, and then either remained stable in dogs with
sustained grafts or began to decline in dogs that subse-
quently rejected the donor grafts. The percent of donor
chimerism at 5 weeks posttransplantation did not predict
the development of stable mixed chimerism when all recipi-
ents were considered together. However, percent donor
chimerism greater than 10% in mononuclear cells or 40%
in granulocytes was associated with stable engraftment in
group 2 dogs.
DISCUSSION
Previous studies have shown that donor engraftment is
achieved uniformly in dogs receiving DLA-identical marrow
grafts after myeloablative conditioning without the addition
of postgrafting immunosuppression [18]. In contrast, both
the type and duration of immunosuppression affected donor
engraftment after nonmyeloablative conditioning [18].
This study demonstrates that the composition of the stem
cell graft can also affect donor engraftment in nonmyeloab-
lated recipients. The addition of unmodiﬁed G-PBMCs to
marrow cells enhanced the development of stable mixed
hematopoietic chimerism tested in a stringent canine trans-
plantation model. Interestingly, it was previously reported
that viable steady-state PBMCs added to DLA-identical mar-
row grafts in dogs conditioned with 450 cGy did not enhance
allogeneic engraftment [28]. This ﬁnding suggests that the
function and consequently the effect of the G-PBMC product
in vivo may indeed be different from steady-state PBMCs
consistent with results from in vitro studies [7,13].
Figure 1. Total number of CD14, CD3, and CD34 cells infused into
recipients. The control group received cryopreserved marrow only. The
experimental groups received the indicated G-PBMC population (x axis)
in addition to the cryopreserved marrow. Gray bars indicate dogs that
remained stable mixed chimeras; white bars indicate dogs that rejected
their grafts. Dogs are listed in the same order in Figures 1 and 2.
Figure 2. Degree of donor chimerism in peripheral blood granulo-
cytes and mononuclear cells at week 5 after transplantation. Gray bars
indicate dogs that remained stable mixed chimeras; white bars indicate
dogs that rejected their grafts between weeks 8 and 18 after transplan-
tation. Dogs are listed in the same order in Figures 1 and 2.
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In vitro studies using both canine and human cells indi-
cated that T cells in G-PBMCs are hyporesponsive to
alloantigen stimulation [7,16]. Further studies using human
cells indicated that T-cell nonresponsiveness could be
attributed to the large numbers of monocytes present in the
G-PBMC product. These monocytes were also qualitatively
different in that they secreted increased amounts of IL-10
and had decreased expression of costimulatory molecules,
both of which served to reduce T-cell proliferative responses
[17]. Based on these observations, we hypothesized that
CD14+ monocytes may facilitate engraftment by reducing
both graft-versus-host and host-versus-graft reactions.
However, our data indicate that in the absence of CD3 cells,
the addition of G-PBMC–derived CD14 cells is not sufﬁ-
cient to facilitate engraftment in this model.
Dogs receiving transplants of marrow plus CD3-
depleted G-PBMCs received the largest number of CD34
cells, yet only 1 of 7 of these recipients developed stable
mixed chimerism. These data suggest that the larger num-
ber of CD34 cells provided by the G-PBMC product is also
not sufficient for facilitating engraftment. Clearly, T cells
are required; however, whether they alone are sufﬁcient is
not addressed by this study.
Clinical studies in humans have documented the role of
T cells in the engraftment of allogeneic cells after myeloab-
lative hematopoietic stem cell transplantations [29,30]. We
have also shown that after myeloablative conditioning,
T cell depletion of donor grafts in DLA-identical dogs was
associated with graft rejection [31,32]. The results of the
current study showed that the number of T cells is also
important to engraftment in the nonmyeloablated recipi-
ents. It is believed that donor T cells facilitate engraftment
by eliminating or suppressing host lymphocytes [33]. How-
ever, which subset of human or canine T cells contains the
engraftment-facilitating cells is not yet clearly determined
[34-37]. T lymphocytes capable of facilitating engraftment
without causing GVHD have been identiﬁed in the mouse
model as the Tc type 2 subset of CD8+ cells [38,39].
In the current study, all 3 groups contained dogs that
rejected their grafts and dogs that developed stable mixed
chimerism. Intragroup differences in the number of CD3,
CD14, and CD34 cells do not explain these ﬁndings. The
results of blood CSP monitoring (data not shown) indicated
that there were no significant differences in the degree of
recipients’ pharmacological immunosuppression. Therefore,
other factors in addition to T-cell number, such as the
degree of disparity in minor histocompatibility antigens or
yet-undefined differences in the cell composition of the
graft, may also inﬂuence donor cell engraftment in nonmye-
loablated recipients.
We conclude that the cell composition of hematopoietic
stem cell grafts appears to affect donor cell engraftment in
nonmyeloablated canine recipients. The addition of G-PBMCs
to cryopreserved marrow grafts replaced the requirement of
MMF and 100 cGy of TBI to achieve stable mixed chimerism.
G-CSF–mobilized T cells were required, whereas additional
CD14 and CD34 cells were not sufﬁcient.
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